Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tongjitang Reports a Down Q3

publication date: Nov 25, 2008

Tongjitang Chinese Medicines Company (同济堂药业) released another in a year-long series of disappointing earnings reports. In its Q3, Tongjitang’s revenues dropped 13% to 110 million RMB ($16.3 million), and net income fell 86% to 7 million RMB ($1.1 million), which is equivalent to earnings per ADS of 3 cents. The company also lowered its official revenue guidance for 2008 to 450 million RMB, down from 596 million RMB last year. There was a small measure of good news in the earnings announcement. More details...

Stock Symbol: (NYSE: TCM)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here